<DOC>
	<DOCNO>NCT00668070</DOCNO>
	<brief_summary>The aim study explore effect new drug ( ASP9831 ) patient non-alcoholic steatohepatitis ( NASH ) assess clinical sign , laboratory data biomarkers 12 week treatment period</brief_summary>
	<brief_title>A Proof-of-principle Study Oral Treatment Non-alcoholic Steatohepatitis With Novel PDE4 Inhibitor ASP9831</brief_title>
	<detailed_description>The study include open-label sub-study prior main study</detailed_description>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Phosphodiesterase 4 Inhibitors</mesh_term>
	<criteria>NASH , histologically confirm liver biopsy perform within 1 year prior first dose randomization Elevated serum ALT level Hepatic cirrhosis Other know cause liver disease Uncontrolled diabetes mellitis type 2 , i.e . HbA1c &gt; 8.5 % Positive history tuberculosis positive PPD skin test explain previous BCG vaccination History excessive alcohol abuse within 5 year prior screen current average alcohol intake 20 g/day ( 2 unit ) females 30 g/day ( 3 unit ) male Subject use drug associate steatohepatitis within 6 month prior screen ( corticosteroid , high dose estrogen , methotrexate , amiodarone , antiHIV drug , tamoxifen )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>NASH</keyword>
	<keyword>Chronic liver disease</keyword>
</DOC>